Acevaltrate, an active component derived from the herbal plant Valeriana jatamansi Jones, is strikingly potent to induce GBM cell apoptosis. Acevaltrate inhibits the Na+/K+-ATPase activity in the rat kidney and brain hemispheres with IC50 of 22.8 μM and 42.3 μM, respectively.
Acevaltrate disrupts the interaction of Otub1/c-Maf thus inhibiting Otub1 activity and leading to c-Maf polyubiquitination and subsequent degradation in proteasomes. Consistently, acevaltrate inhibits c-Maf transcriptional activity and downregulates the expression of its target genes key for myeloma growth and survival.[1]
Acevaltrate displays potent anti-myeloma activity by triggering myeloma cell apoptosis in vitro and impairing myeloma xenograft growth in vivo but presents no marked toxicity.[1]
[1] Bettero GM, et al. Planta Med. 2011 Oct;77(15):1702-6. [2] Sun T, et al. Cell Commun Signal. 2021 Feb 24;19(1):24.